These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 23163616)
1. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Kelly CP; Green PH; Murray JA; Dimarino A; Colatrella A; Leffler DA; Alexander T; Arsenescu R; Leon F; Jiang JG; Arterburn LA; Paterson BM; Fedorak RN; Aliment Pharmacol Ther; 2013 Jan; 37(2):252-62. PubMed ID: 23163616 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Leffler DA; Kelly CP; Abdallah HZ; Colatrella AM; Harris LA; Leon F; Arterburn LA; Paterson BM; Lan ZH; Murray JA Am J Gastroenterol; 2012 Oct; 107(10):1554-62. PubMed ID: 22825365 [TBL] [Abstract][Full Text] [Related]
3. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Leffler DA; Kelly CP; Green PH; Fedorak RN; DiMarino A; Perrow W; Rasmussen H; Wang C; Bercik P; Bachir NM; Murray JA Gastroenterology; 2015 Jun; 148(7):1311-9.e6. PubMed ID: 25683116 [TBL] [Abstract][Full Text] [Related]
4. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Hoilat GJ; Altowairqi AK; Ayas MF; Alhaddab NT; Alnujaidi RA; Alharbi HA; Alyahyawi N; Kamal A; Alhabeeb H; Albazee E; Almustanyir S; Abu-Zaid A Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101782. PubMed ID: 34339872 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096 [TBL] [Abstract][Full Text] [Related]
6. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Leffler D; Schuppan D; Pallav K; Najarian R; Goldsmith JD; Hansen J; Kabbani T; Dennis M; Kelly CP Gut; 2013 Jul; 62(7):996-1004. PubMed ID: 22619366 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Tye-Din JA; Daveson AJM; Goel G; Goldstein KE; Hand HL; Neff KM; Popp A; Taavela J; Maki M; Isola J; Williams LJ; Truitt KE; Anderson RP; Lancet Gastroenterol Hepatol; 2023 May; 8(5):446-457. PubMed ID: 36898393 [TBL] [Abstract][Full Text] [Related]
8. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease. Murray JA; Kelly CP; Green PHR; Marcantonio A; Wu TT; Mäki M; Adelman DC; Gastroenterology; 2017 Mar; 152(4):787-798.e2. PubMed ID: 27864127 [TBL] [Abstract][Full Text] [Related]
9. Dietary and symptom assessment in adults with self-reported non-coeliac gluten sensitivity. Skodje GI; Minelle IH; Rolfsen KL; Iacovou M; Lundin KEA; Veierød MB; Henriksen C Clin Nutr ESPEN; 2019 Jun; 31():88-94. PubMed ID: 31060839 [TBL] [Abstract][Full Text] [Related]